| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.098 | 0.003 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.089 | 0.004 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.17 | 0.004 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | StemRegenin 1 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.005 |